Viewing Study NCT03169959

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 3:01 PM
Ignite Modification Date: 2026-07-05 @ 11:41 AM
Study NCT ID: NCT03169959
Status: COMPLETED
Last Update Posted: 2017-08-14
First Post: 2017-05-23
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.
Sponsor: AstraZeneca
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Type 2 Diabetes Mellitus View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Anti-diabetic View
None Anti-hyperglycemic agents View
None Bioequivalence View
None Fixed-Combination Drug Product (FCDP) of saxagliptin / dapagliflozin / metformin … View
None Fed-state bioequivalence (BE) View
None XIGDUO® XR View
None ONGLYZA® View